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ABSTRACT 
 
Aims: To present the molecular structures of compounds that has been shown to inhibit the 
proliferation of Ebola virus. To elucidate the molecular properties of these virus inhibiting 
compounds.  
Study Design: The molecular properties of virus inhibiting compounds are elucidated and 
compiled. Pattern recognition methods and statistical analysis are applied to determine optimal 
properties of this group of compounds. 
Place and Duration of Study: Chemistry Department, Durham Science Center, University of 
Nebraska, Omaha NE. between December 2015 and February 2016. 
Methodology: A total of 60 compounds were identified as inhibiting the virus Ebola. The molecular 
properties such as Log P, molecular weight, and 7 other descriptors were elucidated utilizing 
heuristic methods. Structures are compared by applying classification methods with statistical tests 
to determine trends, underlying relationships, and pattern recognition.  
Results: For 60 compounds identified the averages determined: for Log P (3.51), polar surface 
area (89.45 Angstroms2), molecular weight (432.6), molecular volume (393.96 Angstroms3), and 
number of rotatable bonds (7). Molecular weight showed a strong positive correlation to number of 
oxygen and nitrogen atoms, number of rotatable bonds, and molecular volume. K-means clustering 
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indicated seven clusters divided according to highest similarity of members in the cluster. Ranges 
found: formula weights (157.1 to 822.94), Log P (-2.24 to 8.93), polar surface area (6.48 to 267.04 
A2), and number of atoms (11 to 58). Multiple regression analysis produced an algorithm to predict 
similar compounds.  
Conclusion: The formula weights and Log P values of Ebola virus inhibitors show a broad range in 
numerical values. Consistency in properties was identified by statistical analysis with grouping for 
similarity by K-means pattern recognition.  Multiple regression analysis enables prediction of similar 
compounds as drug candidates. Only 29 compounds showed zero violations of rule of 5, an 
indication of favorable drug-likeness. These compounds are highly varied in structures and 
properties. 
 
 
Keywords: Ebola virus; virus; drug-likeness; Ebolavirus; hemorrhagic; EVD. 
 
ABBREVIATIONS 
 
PSA, polar surface area; nAtoms, number of atoms; nON, number of oxygen and nitrogen atoms; 
nOHNH, number of hydroxyl and amine groups; nRotB, number of rotatable bonds; MV, molecular 
volume; MW, molecular weight; SMILES, simplified molecular-input line-entry system; EVD, Ebola 
virus disease. 
 
1. INTRODUCTION  
 
The Ebola virus is one of known viruses within 
the genus Ebolavirus that are generally 
considered to cause Ebola virus disease (EBV) 
in humans. The Ebola virus is one five viruses 
that exist within the genus Ebolavirus, order 
Mononegavirales, family Filoviridae, and the 
single member of the species Zaire ebolavirus 
[1]. Four of the five Ebola viruses induce a very 
severe and very often fatal hemorrhagic fever in 
mammals, as well as humans [1]. At present, the 
reservoir for this virus in nature is considered to 
be bats (i.e. fruit bats) and the primary mode of 
transference to humans is by body fluids [2]. The 
Ebola virus is a zoonotic pathogen (a disease 
that can be passed between animals and 
humans and zoonotic diseases can be caused by 
viruses, bacteria, parasites, and fungi) [2].  
 
Some investigators have determined that Ebola 
virus outbreaks have an increased likelihood to 
occur when temperatures are lower and humidity 
is higher [3]. Post recovery, the virus can survive 
for months in certain organs (i.e. eyes and 
testes) [3]. A major concern for clinicians is a 
delayed diagnosis of Ebola resulting in delayed 
treatment, severe illness, death, and 
transmission into areas thought cleared of the 
virus [4]. Deliberate evasion of control 
intervention actions is very problematic in 
monitoring possible contacts and identification of 
potential cases [4]. 
 
Direct contact with body fluids is generally 
considered to be the major risk factor for 
contracting the virus [5]. Being a viral 
hemorrhagic fever, it is common to observe 
blood abnormalities, such as decreased platelets 
[6]. However, there are other organs involved 
that include renal, cardiac, lung, gastrointestinal, 
neurological and hepatic indicators [6]. A high 
fever and hemorrhagic manifestations 
(hemorrhagic conjunctivitis, bleeding ulcerations 
of mouth and lips, gingival bleeding, 
hematemesis, ear bleeding, hematuria) are 
generally observed in patients [6].  
 
The Ebola virus is known to be isolable in semen 
(82 days after illness onset) [7,8], aqueous 
humor (on day 63 after illness onset) [7], sweat 
[7], urine (after 26 days after illness onset) [7], 
vaginal secretions (on day 33 after illness onset), 
feces [7], and breast milk (15 days after illness 
onset) [7]. Sexual contact has been shown to be 
an effective mode of transmitting the virus [8]. 
Other viral hemorrhagic fevers include Marburg 
disease and Lassa fever, and all can be easily 
imported into any part of the industrialized world 
[9]. For EBV disease identified in Guinea, the 
symptoms included severe diarrhea, vomiting, 
and dehydration [10].  
 
The determination and evaluation of 
pharmacokinetic and pharmacodynamics 
properties of drugs potentially useful for 
treatment of Ebola virus disease is a very 
important consideration for discovery of new 
pharmaceuticals [11]. Establishing these criteria 
for the molecular properties of novel potential 
drug candidates well expedite identification                    
of likely compounds and enhance the 
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commencement of human trials [11]. Similar 
approaches in past studies have already been 
proven to be useful for drug classes such as anti-
inflammatories [12], anticancer agents [13], and 
development of selective COX-2 inhibitors [14].  
This study seeks to establish a criteria for 
molecular properties of a broad range of 
compounds previously shown to inhibit the 
proliferation of Ebola virus. 
 
2. METHODOLOGY  
 
2.1 Properties and Molecular Modeling  
 
Numerical values of molecular properties and 
descriptors of the compound’s molecular 
structures were calculated by utilizing 
Molinspiration (Molinspiration Cheminformatics, 
Nova ulica 61, SK-900 26 Slovensky Grob, 
Slovak Republic). Additional elucidation of 
structure components was accomplished through 
the use of ACD ChemSketch Modeling v. 12.01 
(Advanced Chemistry Development, 110 Yonge 
Street, Toronto Ontario, M5C 1T4 Canada, 
http://www.molinspiration.com/services/search.ht
ml).     
 
2.2 Pattern Recognition and Multivariate 
Statistical Analysis 
 
To identify underlying associations and patterns 
within the numerical properties the use of various 
pattern recognition techniques was applied. In 
addition, analysis of non-hierarchical K-means 
cluster analysis and 95% ellipses were 
performed by PAST v. 2.06 (copyright Oyvind  
Hammer, D.A.T. Harper 1999-2008)  and KyPlot 
v. 2.0 Beta 15 (copyright Koichi Yoshioka 1997-
2001) 
 
2.3 Various Statistical Analysis Data  
 
Statistical analysis of numerical data, including 
Pearson r correlation and descriptive statistics 
were accomplished by Microsoft EXCEL v. 
14.0.6112.5000 (EXCEL Professional plus 2010).  
Multiple regression analysis of molecular 
property values was accomplished by GraphPad 
Instat version 3.00 (GraphPad Software, Inc., 
San Diego, California USA; www.graphpad.com).  
Determination of any numerical outliers was 
accomplished by applying Grubb’s test (also 
known as extreme studentized deviate).  
Standard 2-way plotting and box plots were 
accomplished for visual representation by PAST 
v. 2.06. 
3. RESULTS AND DISCUSSION 
 
Quick development of efficient drugs for the 
treatment of Ebola virus infection is a most 
urgent issue to rescue multitudes of Ebola-
infected patients [15]. An antibody therapeutic 
referred to as ZMapp is under development and 
testing [15]. ZMapp is comprised of an antibody 
cocktail that mixes the humanized mAbs with a 
selected composition of c13C6 from MB-003 
(human-mouse chimeric mAbs developed by 
Mapp Biopharmaceutical Inc., San Diego, CA, 
USA) and c2G4 and c4G7 from ZMAb (mouse 
mAbs developed by DeFyrus, Toronto, Canada). 
Unfortunately, due to the fact that Ebola virus 
disease did not generate an outbreak frequently, 
any vaccine research and development was only 
slowly studied and pursued [15]. A major pursuit 
of medical professionals encountering infected 
individuals is to provide Ebola patients with basic 
supportive care such as sustaining hydration. 
Clinicians must also ensure that infected patients 
interaction with others is limited to prevent 
transmission. 
 
This study will show the structures and molecular 
properties of 60 compounds that have been 
shown to inhibit Ebola virus proliferation [16]. 
This analysis will determine statistical features 
useful for consideration of similar potential 
compounds. Pattern recognition did elucidate 
underlying relationships of the property values.  
Multiple regression analysis produced a 
mathematical algorithm useful for determining 
individual properties of perspective candidate 
compounds, these being properties important to 
pharmacodynamics (drugs at the site of action 
and resulting effect) and pharmacokinetics (time 
course of drug absorption, distribution, 
metabolism, and excretion). 
 
The properties of compounds presented here will 
be seen to vary broadly. The physiological 
functions of these 60 compounds are also broad 
and include the following groups of biological 
activity: viral transcription modulators, protease 
inhibitors, PCK C1 (NPC-1) small molecules, 
kinase inhibitors, phosphatase inhibitors, ion 
channel modulators, microtubule modulators, 
actin modulators, glycosylation modulators, 
budding modulators, and various small molecule 
organic compounds [16]. 
 
3.1 Structure and Molecular Properties of 
EBOLA Inhibiting Compounds  
 
Structures of compounds 1 to 9 are presented in 
Fig. 1. With compounds 1 to 5 being viral 
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transcription modulators and compounds 5 to 9 
are protease inhibitors [16]. What is quickly 
apparent from compounds 1 to 9, and descript 
for others presented here, is the broad range in 
size, heteroatom rings, functional groups, and 
functional groups (see Fig. 1). The numerical 
values of molecular properties for all 60 
compounds are shown in Table 1.  
 
Interestingly, upon analysis of numerical values 
of the descriptors from Table 1 by Grubb’s test 
showed no outliers in values of molecular weight, 
Log P, the number of atoms, number of rotatable 
bonds, number of hydroxyl groups (-OH), and 
number of amine groups (-NHn). This outcome 
despite the broad variety in molecular structures 
shown in Figs. 1, 2, 3, 4, 5, 6, and 7. Actually, 
only in polar surface area is one outlier 
compound found (56), in addition, only one 
outlier compound is found in molecular volume 
(29).  
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Fig. 1. Structures and SMILES notation for antiviral compounds 1 to 9. Compounds 1 to 5 are 
viral transcription modulators. Compounds 5 to 9 are protease inhibitors 
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Compounds 10 to 13 are protease inhibitors (see 
Fig. 2). Compounds 14 to 17 are (NPC1)-
dependent small molecule virus inhibitors [16].  
Various functional groups, aromatic ring, and 
alkyl chains are evident on these various 
scaffoldings. 
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Fig. 2. Molecular structures and SMILES notation for antiviral compounds 10 to 17.  
Compounds 10 to 13 are protease inhibitors. Compounds 14 to 17 are (NPC1)-dependent virus 
inhibitors. Note structure 10 is a positively charged species 
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Compounds 18, 19, and 20 are (NPC1)-
dependent; with 21 to 27 being phosphatase and 
kinase inhibitors (see Fig. 3) [16]. Aromatic rings 
are typical for this group. 
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Fig. 3. Molecular structures and SMILES notation for antiviral compounds 18 to 27. 
Compounds 18 to 20 are (NPC1)-dependent small virus inhibitors. Compounds 21 to 27 are 
kinase and phosphatase inhibitors 
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Aromatic rings are typical for the kinase and 
phosphatase inhibitors of 28 to 29; ion channel 
compounds 30 to 33; and actin/microtubule 
modulators 34, 35 (see Fig. 4) [16]. 
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Fig. 4. Molecular structures and SMILES notation of antiviral compounds 28 to 35. Compounds 
28 to 29 are kinase and phosphatase inhibitors. Compounds 30 to 33 are ion channel 
modulators. Compounds 34 and 35 are microtubule and actin modulators 
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In Fig. 5, there are glycosylation (36, 37, 38)               
and budding (i.e. budding from membrane) 
modulators. Structures 41 to 45 are small 
molecules expressing Ebola virus inhibitors [16].  
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Fig. 5. Molecular structures and SMILES notation of antiviral compounds 36 to 45. Compounds 
36 to 38 are glycosylation modulators.  Compounds 39 and 40 are budding modulators. 
Compounds 41 to 45 are various small molecule Ebola virus inhibitors [16] 
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Compounds shown in Fig. 6 are various small 
molecule viral inhibitors (save for 46 being a 
budding modulator) [16]. Compounds in Fig. 7 
are among the largest of the 60 members and 
incorporate large internal ring structures and also 
diverse heteroatom groups. 
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Fig. 6. Molecular structures of antiviral compounds 46 to 54. Compound 46 is a budding 
modulator. Compounds 47 to 54 are small molecule Ebola virus inhibitors 
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Fig. 7. Molecular structures and SMILES notation of antiviral compounds 55 to 60. Compounds 
55 and 56 are budding modulators. Compounds 57 to 59 are microtubule and actin modulators. 
Compound 60 is a budding modulator 
 
Statistical analysis and pattern recognition 
analysis of properties will reveal underlying 
relationships of these numerical values 
determined for compounds 1 to 60 (see Table 1). 
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Table 1. Molecular properties of compounds 
 
Compound Log P Polar surface area 
(Angstroms2) 
Number of 
atoms 
Molecular 
weight 
Oxygen 
nitrogen 
atoms 
Number of 
OH and NHn 
groups 
Rule of 5 
violations 
Rotatable 
bonds 
Volume 
(Angstroms3) 
1 -0.98 88.85 11 157.1 5 3 0 1 119.06 
2 -2.24 140.31 19 265.27 8 7 1 2 225.72 
3 -1.13 130.32 19 265.27 8 5 0 2 226.35 
4 -1.14 130.32 19 263.26 8 5 0 2 220.13 
5 4.31 114.83 41 620.46 10 0 1 8 492.1 
6 1.88 97.03 24 342.44 7 2 0 11 335.67 
7 -1.37 169.93 25 357.41 10 7 1 12 330.98 
8 -1.93 128.33 26 369.42 9 3 0 8 338.96 
9 0.16 166.27 30 426.56 10 7 1 15 422.72 
10 1.93 131.69 40 543.64 9 3 1 14 508.68 
11 4.95 138.1 39 537.62 11 4 2 10 490.72 
12 2.45 116.06 23 321.38 9 2 0 9 304.06 
13 2.67 116.06 23 321.38 9 2 0 9 303.7 
14 4.64 29.54 28 387.61 3 0 0 6 405.62 
15 4.16 6.48 21 280.42 2 0 0 4 287.31 
16 5.04 88.18 42 573.73 8 1 2 11 543.75 
17 5.78 12.47 27 377.92 2 0 1 7 356.31 
18 6.06 12.47 29 405.97 2 0 1 9 389.91 
19 6.58 29.54 28 448.38 3 0 1 12 380.93 
20 4.55 64.9 36 532.47 8 0 1 8 462.72 
21 3.64 42.68 23 307.35 4 0 0 2 278.13 
22 4.48 70.08 33 466.6 6 1 0 11 428.61 
23 5.07 48.91 25 330.36 3 2 1 3 292.05 
24 5.22 53.6 29 404.51 4 2 1 6 360.35 
25 2.27 90.89 20 270.24 5 3 0 1 224.05 
26 3.93 56.28 22 315.76 5 1 0 4 268.16 
27 4.99 97.63 39 529.53 8 2 1 7 446.63 
28 3.89 86.28 37 493.62 8 2 0 7 461.44 
29 6.11 162.62 58 817.07 12 4 3 11 786.22 
30 8.31 42.68 31 645.32 4 0 2 11 437.04 
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Compound Log P Polar surface area 
(Angstroms2) 
Number of 
atoms 
Molecular 
weight 
Oxygen 
nitrogen 
atoms 
Number of 
OH and NHn 
groups 
Rule of 5 
violations 
Rotatable 
bonds 
Volume 
(Angstroms3) 
31 7.94 88.85 39 556.77 7 1 2 18 533.46 
32 4.55 63.97 33 454.61 6 0 0 13 454.3 
33 5.72 144.52 38 516.55 8 5 2 6 457.44 
34 2.79 84.09 21 301.33 6 2 0 4 246.9 
35 1.1 83.11 29 399.44 7 1 0 5 364.15 
36 1.33 93.38 26 375.41 6 4 0 9 338.63 
37 2.35 104.46 30 428.61 7 4 0 10 436.32 
38 2.72 116.49 31 443.63 8 5 0 10 448.73 
39 3.13 83.98 25 352.42 6 2 0 4 305.39 
40 4.84 24.73 23 320.29 2 0 0 3 260.99 
41 3.58 58.37 22 413.26 5 1 0 7 301.35 
42 3.16 12.47 21 281.4 2 0 0 4 283.8 
43 3.48 20.31 22 309.43 2 0 0 0 284.23 
44 8.93 60.68 34 460.66 3 3 1 6 466.57 
45 0.47 137.67 26 346.39 7 7 1 4 306.64 
46 3.77 63.05 32 445.59 6 1 0 5 405.9 
47 5.38 48.38 24 341.84 4 2 1 5 308.75 
48 5.96 53.34 34 452.6 4 0 1 9 440.81 
49 5 28.16 22 319.88 3 1 1 8 313.12 
50 7.67 57.17 32 466.41 4 3 1 6 409.58 
51 4.72 56.31 34 458.65 6 2 0 10 458.26 
52 6.6 78.78 35 577.43 8 1 2 7 436.37 
53 4.8 114.69 44 620.87 8 3 1 7 630.37 
54 -2.18 206.6 41 584.66 12 8 3 4 520.54 
55 2.11 166.29 43 599.73 11 5 2 7 570.06 
56 1.97 267.04 58 822.94 16 8 3 7 741.93 
57 4.11 95.86 35 479.62 6 3 0 2 460.9 
58 3.52 84.86 29 421.56 6 2 0 1 391.39 
59 2.89 112.93 37 507.63 7 3 1 4 479.11 
60 3.84 92.9 37 517.61 8 2 1 7 453.35 
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The descriptor polar surface area [17] have been 
demonstrated to be good a predictor of drug 
absorption and membrane permeation [17].  
Previous studies have shown that the values of 
polar surface area of less than 80 Angstroms2 
can result in greater than 50% of an orally 
administered drug to be absorbed from the 
gastro-intestines [17]. This encompasses 26, or 
about half the total of 60 compounds. 
Comparison of molecular weight to Log P                 
has results seen in Fig. 8. The Log P values 
range from -2.24 to 8.93, within a molecular 
weight range of 157.1 to 822.94 (see Plot A in 
Fig. 8). 
 
 
 
Fig. 8. Comparison of molecular weight to Log P for all compounds (Plot A). Results of 95% 
ellipses analysis (Plot B), with only outliers 29, 56, and 54 
 
  
 
 
Bartzatt; IJTDH, 15(2): 1-17, 2016; Article no.IJTDH.25021 
 
 
 
14 
 
The 95% confidence ellipses shown in Plot B, 
Fig. 8, are derived from the confidence ellipse                  
that is the smallest ellipse that will cover                    
95% of the all points. Studies have shown                    
that Log P is quite useful for predicting 
membrane permeation [18]. Note that only 
compounds 29, 56, and 54 are the only non-
assimilated compounds of the entire group of 60 
compounds, within the ellipses. This is an 
interesting outcome for 60 diverse compounds 
and indicates a consistent feature within                    
this broad group of Ebola viral inhibiting                
compounds.  
 
The Rule of 5 states that a compound is                  
more likely to be membrane permeable and 
easily absorbed by the body if it matches the 
following criteria [18]: 1) Molecular weight is                    
less than 500; 2) The compound's lipophilicity, 
known as Log P (the logarithm of the partition 
coefficient between water and 1-octanol), is less 
than 5; 3) The sum of hydroxyl and amine groups 
in a drug molecule is less than 5; and 4) The  
sum of oxygen and nitrogen atoms is less than 
10.   
 
A total of 29 of the 60 compounds show zero 
violations of the Rule of 5 (see Table 1). These 
29 compounds would be considered to be orally 
active drugs, membrane permeable, and easily 
absorbed by the body due to matching the 
criteria of Rule of 5 [18]. 
The box plot is a standardized way of displaying 
the distribution of data based on a five number 
summary: minimum, first quartile, median, third 
quartile, and maximum (see Fig. 9) [19]. 
 
Although the range of molecular weight is quite 
broad (157.1 to 822.94), this is not the case for 
the number of oxygen atoms & nitrogen atoms 
(nON), hydroxyl groups & amine 
groups(nOHNHn), and rotatable bonds (nRotB) 
(see box plots, Fig. 9). Ranges in values for 
nON, nOHNHn, and nRotB are as follows, 
respectively: 2 to 16, 0 to 8, and 1 to 18. These 
criteria could be effective in identifying potential 
drug candidates by restricting these descriptors 
to match these parameters. The number of 
atoms ranged from 11 to 58, with compound 56 
as an outlier. 
 
Correlation (Pearson’s r) among molecular 
properties (see Table 1) varied widely. A 
moderate positive correlation (0.3000 < r < 
0.3900) exists between Log P to nAtoms, and 
Log P to molecular volume. A strong positive 
correlation (0.7000 < r < 1.000) exists between 
polar surface area to nOHNHn, nAtoms to the 
Rule of 5, and molecular weight to volume. A 
very negative correlation (-0.4000 to -0.6900) 
exists between Log P to nON, and Log P to 
nOHNHn. Again, correlation relationships among 
properties of candidate drugs may be used for 
selection of optimal candidates.  
 
 
 
Fig. 9. Box plots of all numerical values of number of atoms (nAtoms), number of oxygen & 
nitrogen atoms (nON), number of hydroxyl (-OH) & amine (-NHn) groups (nOHNH), and number 
of rotatable bonds (nRotB). Note that compound 56 is an outlier for nAtoms, nON, and nOHNH.  
Compound 31 is an outlier for nRotB 
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3.2 Prediction by Multiple Regression 
Analysis 
 
There are two major purposes for multiple 
regression [19]: 1) First, one use of multiple 
regression is a prediction or estimation of an 
unknown, dependent value corresponding to a 
set of independent values; 2) A second use of 
multiple regression is to understand the 
functional relationships between the dependent 
and independent variables, in order to determine 
the cause of the variation in the dependent 
variable.  
 
Multiple regression analysis is a powerful 
technique used for predicting the unknown value 
of a variable from the known value of two or 
more variables- also called the predictors. 
Applying the multivariate properties in Table 1 to 
multiple regression analysis, with the purpose of 
predicting molecular weight (dependent variable) 
based on proposed values for seven properties 
(independent variables). Prediction of molecular 
weight MW-molecular weight utilizing seven 
properties including PSA- polar surface area and 
MV-molecular volume. The resulting 
mathematical model (shown below) accounts for 
94.25% of the variance in the molecular weight:  
 
MW = 6.018 + 8.750 (Log P) + 0.3072(PSA) 
+ 6.597(nAtoms) + 5.667(nON) – 
5.342(nOHNH) – 0.2900(nRotB) + 
0.3706(MV) 
 
The independent variables Log P and number of 
atoms (nAtoms), provide the greatest 
contribution within the model.  Only the property 
nOHNH (number of hydroxyl and amine groups), 
did not pass the normality test (numerical values 
that are sample from a Gaussian distribution 
[19]) within these descriptors utilized here. Note 
that only the independent variable total number 
of hydroxyl and amine groups (nOHNHn) and 
rotatable bonds (nRotB) have negative 
coefficients (indicating a decrease in molecular 
weight when these variables increases by one). 
The remaining descriptors Log P, polar surface 
area, number of atoms, number of oxygen-
nitrogen atoms, and molecular volume have 
positive coefficients (indicating increase in 
molecular weight when these variables increase 
by one).  
 
3.3 Pattern Recognition Utilizing K-means 
Cluster Analysis 
 
K-means is one of the simplest unsupervised 
learning algorithms that solve the clustering 
problem [19]. The method follows a simple way 
to classify a given data set into a certain number 
of clusters that is assigned and fixed prior to 
analysis [19]. This cluster method is non-
hierarchical. Members of each cluster are 
determined to be the most similar to each other 
based on numerical values of the multivariate 
table of properties. 
 
K-means cluster analysis of Table 1 into seven 
clusters provides a separation and discernment 
of these 60 diverse compounds into groups of 
compounds having highest similarity to each of 
the other members of the cluster [19].  Results of 
K-means cluster analysis into seven cluster 
outcome, are shown (members, common 
structure features): 
 
Cluster 1: Compounds 1, 2, 3, 4, 25 
(heterocyclic ring structures, aromatic rings, 
carbonyl carbons, hydroxyl groups). 
 
Cluster 2: Compounds 5, 10, 11 16, 30, 31, 
52, 53, 54, 55 (aromatic rings, carbonyl 
carbon, amide groups, tertiary amines). 
 
Cluster 3: Compounds 15, 21, 23, 26, 34, 40, 
42, 43, 47, 49 (aromatic ring, heterocyclic 
ring, tertiary amine, carboxylate ester group). 
 
Cluster 4: Compounds 14, 17, 18, 19, 24, 35, 
44, 46, 50, 58 (aromatic rings, tertiary amine, 
methoxy substituents, halogen atoms). 
 
Cluster 5: Compounds 6, 7, 8, 12, 13, 36, 39, 
41, 45 aromatic rings, tertiary amine, hetero 
atom ring, ester group, branched alkyl 
chain).  
 
Cluster 6: Compounds 9, 20, 22, 27, 28, 32, 
33, 37, 38, 48, 51, 57, 59, 60 (large rings, 
aromatic rings, phenolic hydroxyl group). 
 
Cluster 7: Compounds 29, 56 (hydroxyl 
groups, heterocyclic rings, carboxyl groups, 
cycloalkane ring). 
 
Members of each cluster are determined to have 
the highest similarity after analysis of the 
multivariate data Table 1. After identification             
into clusters, members within clusters may 
express similar pharmacodynamics and/or 
pharmacokinetics.  Inferences of potential clinical 
activity may be determined by examination of 
cluster members. Cluster analysis provides 
investigators some means to understand 
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underlying relationships among this diverse 
population of 60 compounds.  
 
Ebola virus remains a pathogen inducing high 
morbidity and mortality. The identification of 
drugs to treat EVD is an urgent necessity, along 
with new methods for screening for such drugs 
[20]. The investigation of compounds previously 
shown to inhibit viral proliferation could enhance 
the effectiveness of recognizing new candidate 
drugs for clinical treatment of infection. Although 
further study is required and crucial, this study 
and similar studies present the molecular 
structures of known virus inhibitors and the 
molecular properties are useful for elucidating 
pharmacokinetics and pharmacodynamics. The 
search for effective virus inhibitors is ongoing.  
 
4. CONCLUSION 
 
The molecular structures of 60 compounds 
shown in previous studies to inhibit viral 
proliferation of Ebola virus are presented with 
numerical values of eight important descriptors.  
Their molecular scaffolding is found to be highly 
diverse, having various heteroatom rings, alkyl 
structures, functional groups, and various 
aromatic substituents. The numerical values of 
eight molecular properties are determined with 
statistical analysis to find ranges and 
correlations. Pattern recognition K-means cluster 
analysis divided the 60 compounds into seven 
clusters having members with the greatest 
similarity based on molecular properties.  
Multiple regression analysis determined a 
mathematical model explaining 94.25% of the 
variance in the molecular weight.  This model will 
enable the prediction of expected properties for 
potential drug candidates. The Rule of 5 
identified 29 compounds out of the total of 60, 
considered to be orally active, membrane 
permeable, and easily absorbed. Box plots 
identified a narrower criteria in the number of 
oxygen atoms, nitrogen atoms, hydroxyl groups, 
amine groups, and rotatable bonds for potential 
drug candidates. Further studies are vital for the 
identification of new drugs to treat patients 
infected with Ebola virus disease. 
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